Literature DB >> 9427141

Expression of human phenylalanine hydroxylase activity in T lymphocytes of classical phenylketonuria children by retroviral-mediated gene transfer.

C M Lin1, Y Tan, Y M Lee, C C Chang, K J Hsiao.   

Abstract

Classical phenylketonuria (PKU) is a metabolic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene. At present, T lymphocyte-directed gene therapy is the only means for which a safety record has been established. Thus, we investigated the applicability of this strategy to PKU gene therapy. We first looked for tetrahydrobiopterin (BH4) and dihydropteridine reductase (DHPR) activity, which are required for the phenylalanine hydroxylation reaction and BH4 regeneration, respectively, in T cells isolated from PKU children. We found that T cells contained a small amount of biopterin, but significant DHPR activity, and that the intracellular biopterin content could be increased by exogenous BH4 supplementation. Moreover, PKU T cells were capable of taking up phenylalanine efficiently and effluxing acquired tyrosine. Finally, a recombinant retrovirus containing the human PAH cDNA was constructed and used to transduce isolated PKU T cells. Viral-transduced T cells produced high levels of PAH activity as compared to control mock-infected T cells. These results indicate that T lymphocytes express all that is required for synthesizing/replenishing constituents of the phenylalanine hydroxylation reaction and expressing transduced phenylalanine hydroxylase cDNA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9427141     DOI: 10.1023/a:1005303331218

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  45 in total

1.  THE STRUCTURE OF THE PHENYLALANINE-HYDROXYLATION COFACTOR.

Authors:  S KAUFMAN
Journal:  Proc Natl Acad Sci U S A       Date:  1963-12       Impact factor: 11.205

2.  High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes.

Authors:  B A Bunnell; L M Muul; R E Donahue; R M Blaese; R A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

3.  Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes.

Authors:  M A Kay; P Baley; S Rothenberg; F Leland; L Fleming; K P Ponder; T Liu; M Finegold; G Darlington; W Pokorny
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

4.  Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy.

Authors:  J Byun; S H Kim; J M Kim; S S Yu; P D Robbins; J Yim; S Kim
Journal:  Gene Ther       Date:  1996-09       Impact factor: 5.250

Review 5.  Inborn errors of pterin metabolism.

Authors:  N Blau
Journal:  Annu Rev Nutr       Date:  1988       Impact factor: 11.848

6.  Prenatal diagnosis of "dihydrobiopterin synthetase" deficiency, a variant form of phenylketonuria.

Authors:  A Niederwieser; H Shintaku; T Hasler; H C Curtius; H Lehmann; O Guardamagna; H Schmidt
Journal:  Eur J Pediatr       Date:  1986-08       Impact factor: 3.183

7.  Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo.

Authors:  Y Yang; K U Jooss; Q Su; H C Ertl; J M Wilson
Journal:  Gene Ther       Date:  1996-02       Impact factor: 5.250

8.  Physical growth in phenylketonuria: II. Growth of treated children in the PKU collaborative study from birth to 4 years of age.

Authors:  V A Holm; R A Kronmal; M Williamson; A F Roche
Journal:  Pediatrics       Date:  1979-05       Impact factor: 7.124

9.  Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope.

Authors:  J S Lam; M E Reeves; R Cowherd; S A Rosenberg; P Hwu
Journal:  Hum Gene Ther       Date:  1996-08-01       Impact factor: 5.695

10.  Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer.

Authors:  J H Wolfe; M S Sands; J E Barker; B Gwynn; L B Rowe; C A Vogler; E H Birkenmeier
Journal:  Nature       Date:  1992 Dec 24-31       Impact factor: 49.962

View more
  7 in total

Review 1.  State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.

Authors:  Hiu Man Grisch-Chan; Gerald Schwank; Cary O Harding; Beat Thöny
Journal:  Hum Gene Ther       Date:  2019-09-09       Impact factor: 5.695

2.  Low tetrahydrobiopterin biosynthetic capacity of human monocytes is caused by exon skipping in 6-pyruvoyl tetrahydropterin synthase.

Authors:  Karin L Leitner; Martina Meyer; Walter Leimbacher; Anja Peterbauer; Susanne Hofer; Christine Heufler; Angelika Müller; Regine Heller; Ernst R Werner; Beat Thöny; Gabriele Werner-Felmayer
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

3.  Towards metabolic sink therapy for mut methylmalonic acidaemia: correction of methylmalonyl-CoA mutase deficiency in T lymphocytes from a mut methylmalonic acidaemia child by retroviral-mediated gene transfer.

Authors:  C C Chang; K J Hsiao; Y M Lee; C M Lin
Journal:  J Inherit Metab Dis       Date:  1999-10       Impact factor: 4.982

Review 4.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

Review 5.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

Review 6.  State-of-the-art 2003 on PKU gene therapy.

Authors:  Zhaobing Ding; Cary O Harding; Beat Thöny
Journal:  Mol Genet Metab       Date:  2004-01       Impact factor: 4.797

7.  Expression of phenylalanine hydroxylase (PAH) in erythrogenic bone marrow does not correct hyperphenylalaninemia in Pah(enu2) mice.

Authors:  Cary O Harding; Mark Neff; Kelly Jones; Krzysztof Wild; Jon A Wolff
Journal:  J Gene Med       Date:  2003-11       Impact factor: 4.565

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.